SCHEMBL5080725

SCHEMBL5080725

O=C(OC[C@@H]1O[C@H](n2cc(F)c(=O)[nH]c2=O)C(OC(=O)c2ccccc2)C1OC(=O)c1ccccc1)c1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.61
▸ USP2 O75604 1/20 0.61
▸ POLB P06746 1/20 0.61
▸ KMT2A Q03164 1/20 0.61
▸ GAPDH P04406 2/20 0.51
▸ CA1 P00915 1/20 0.47
▸ CA2 P00918 1/20 0.47
▸ CA9 Q16790 1/20 0.47
▸ ALDH1A1 P00352 2/20 0.45
▸ RNASE1 P07998 1/20 0.44
▸ P2RY6 Q15077 2/20 0.43
▸ P2RY14 Q15391 2/20 0.43
▸ NT5E P21589 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ LMNA P02545 2/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ TSHR P16473 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ PMP22 Q01453 1/20 0.41
▸ HBB P68871 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9002102 1.00 MEN1 (0.61) MEN1USP2POLBKMT2AGAPDH
SCHEMBL9002093 1.00 MEN1 (0.61) MEN1USP2POLBKMT2AGAPDH
SCHEMBL20983914 1.00 MEN1 (0.61) MEN1USP2POLBKMT2AGAPDH
SCHEMBL7942376 1.00 MEN1 (0.61) MEN1USP2POLBKMT2AGAPDH
SCHEMBL5717456 0.95 MEN1 (0.59) MEN1USP2POLBKMT2AGAPDH
SCHEMBL5717451 0.95 MEN1 (0.59) MEN1USP2POLBKMT2AGAPDH
SCHEMBL9137347 0.94 MEN1 (0.55) MEN1USP2POLBKMT2AGAPDH
SCHEMBL25399138 0.92 MEN1 (0.55) MEN1USP2POLBKMT2AGAPDH
SCHEMBL5717506 0.92 MEN1 (0.55) MEN1USP2POLBKMT2AGAPDH
SCHEMBL5717501 0.92 MEN1 (0.55) MEN1USP2POLBKMT2AGAPDH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080050425-A1 Combination Chemotherapy Comprising 5-Fluorouracil or a Derivative Thereof and a Liposomal Platinum Complex ANTIGENICS, INC. 2008-02-28 — — US disclosed
EP-1631301-A4 COMBINATION CHEMOTHERAPY COMPRISING 5-FLUOROURACIL OR A DERIVATIVE THEREOF AND A LIPOSOMAL PLATINUM COMPLEX ARONEX PHARMACEUTICALS INC (US) 2006-06-07 — — EP disclosed
EP-1631301-A1 COMBINATION CHEMOTHERAPY COMPRISING 5-FLUOROURACIL OR A DERIVATIVE THEREOF AND A LIPOSOMAL PLATINUM COMPLEX Aronex Pharmaceuticals Inc. (US) 2006-03-08 — — EP disclosed
WO-2004103382-A1 COMBINATION CHEMOTHERAPY COMPRISING 5-FLUOROURACIL OR A DERIVATIVE THEREOF AND A LIPOSOMAL PLATINUM COMPLEX ARONEX PHARMACEUTICALS, INC. (US) 2004-12-02 — — WO disclosed
US-4122251-A Process for production of 5-fluorouracil and its derivatives DAIKIN KOGYO CO., LTD. (JP) 1978-10-24 — — US disclosed
Send feedback